ArticleOpen forum infectious diseases2025
Fatal Adverse Event After VLA1553 Chikungunya Vaccination in an Elderly Patient: A Case Report From Reunion Island.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Evidence of Chikungunya Virus Reinfection in Two Patients With Lupus During the 2024-2025 Outbreak on Reunion Island.Open forum infectious diseases · 2026Article
- Five Hot Topics in Tropical Medicine: 2025.Infectious disease reports · 2026Review
- Type I IFN autoantibodies underlie chikungunya live-attenuated vaccine encephalitis.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Chikungunya in 2025: Comprehensive Insights into Virology, Diagnostics, Vaccines, and Antiviral Therapies.Viruses · 2026Review
- Attenuated viral strains of priority pathogens for potential use in controlled human infection model studies: A scoping review.PLoS neglected tropical diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a fatal case of febrile encephalopathy in an 84-year-old man following administration of the live-attenuated chikungunya vaccine IXCHIQ® (VLA1553, Valneva SE) during the 2025 outbreak in Réunion Island. The patient, previously autonomous with stable comorbidities, developed fever, asthenia, and polyarthralgia 3 days post-vaccination. His condition rapidly deteriorated, with confusion, acute kidney injury, and hemodynamic instability requiring intensive care. Chikungunya virus RNA was detected in both serum and cerebrospinal fluid, with sequencing confirming the presence of the vaccine strain in both compartments. Despite broad-spectrum antimicrobials, antiviral therapy targeting herpesviruses, and hemodialysis, his neurological status worsened and he died 14 days after symptom onset. This case is the first fatal adverse event officially recognized by French health authorities as plausibly related to VLA1553 vaccine. It raises concerns regarding potential neuroinvasive disease following vaccination in elderly individuals and highlights the importance of close clinical and virological evaluation in post-vaccination adverse events during outbreak settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.